F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice

被引:0
|
作者
Marie-Bernadette Assié
Laurent Bardin
Agnès Auclair
Nathalie Consul-Denjean
François Sautel
Ronan Depoortère
Adrian Newman-Tancredi
机构
[1] Centre de Recherche Pierre Fabre,
来源
Naunyn-Schmiedeberg's Archives of Pharmacology | 2007年 / 375卷
关键词
Antipsychotic; Mouse brain; F15063; Plasma levels; Apomorphine-induced climbing and sniffing; D2-like receptor occupancy;
D O I
暂无
中图分类号
学科分类号
摘要
F15063 (N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine fumarate salt) is a novel potential antipsychotic with dopamine D2/D3 blocking properties and agonist activity at 5-HT1A and D4 receptors. The pertinent parameter for pharmacological activity of antipsychotics appears to be central D2-like receptor occupancy. However, its duration is not necessarily correlated with drug plasma levels, on which clinical dosing regimens are often based. Thus, we compared in mice the duration of actions of F15063 and haloperidol to (1) inhibit apomorphine-induced climbing and sniffing (behavioural measures of D2-like receptor antagonism) and (2) occupy D2-like receptors in vivo in the striatum and olfactory tubercles (inhibition of [3H]nemonapride binding). Finally, we measured plasma levels of F15063. D2-like receptor occupancy in the striatum remained elevated at 1, 4 and 8 h postadministration, with both F15063 (ID50: 7.1, 3.6 and 16.5 mg/kg p.o., respectively) and the typical antipsychotic, haloperidol (ID50: 1.4, 0.52 and 0.53 mg/kg p.o., respectively). This was paralleled by a protracted inhibition of apomorphine-induced climbing (ED50: 0.9, 2.8 and 3.6 mg/kg p.o., and 0.21, 0.37 and 0.87 mg/kg p.o., respectively, for F15063 and haloperidol). In contrast, after administration of 10 mg/kg p.o. of F15063, its plasma levels decreased rapidly: 15.2, 2.1 and 0.6 ng/ml, 1, 4 and 8 h after administration, respectively. A similar pattern of results was observed when F15063 and haloperidol were administered i.p. and s.c., respectively. To summarise, the time-course of D2-like receptor occupancy and inhibition of apomorphine-climbing (and sniffing) behaviours was similarly long lasting with F15063 and haloperidol. In addition, the durations of action of F15063 and haloperidol in a behavioural model of antipsychotic-like activity were closely correlated to their occupancy of central D2-like receptors, and much longer than their presence in plasma.
引用
收藏
页码:241 / 250
页数:9
相关论文
共 16 条
  • [1] F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties:: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice
    Assie, Marie-Bernadette
    Bardin, Laurent
    Auclair, Agnes
    Consul-Denjean, Nathalie
    Sautel, Francois
    Depoortere, Ronan
    Newman-Tancredi, Adrian
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2007, 375 (04) : 241 - 250
  • [2] F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties:: (I) in vitro receptor affinity and efficacy profile
    Newman-Tancredi, A.
    Assie, M-B
    Martel, J-C
    Cosi, C.
    Slot, L. Bruins
    Palmier, C.
    Rauly-Lestienne, I.
    Colpaert, F.
    Vacher, B.
    Cussac, D.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (02) : 237 - 252
  • [3] Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties
    Bardin, Laurent
    Kleven, Mark S.
    Barret-Grevoz, Catherine
    Depoortere, Ronan
    Newman-Tancredi, Adrian
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 (09) : 1869 - 1879
  • [4] Antipsychotic-Like vs Cataleptogenic Actions in Mice of Novel Antipsychotics Having D2 Antagonist and 5-HT1A Agonist Properties
    Laurent Bardin
    Mark S Kleven
    Catherine Barret-Grévoz
    Ronan Depoortère
    Adrian Newman-Tancredi
    Neuropsychopharmacology, 2006, 31 : 1869 - 1879
  • [5] PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT1A agonist actions.: I.: Neurochemical effects
    Akunne, HC
    Zoski, KT
    Davis, MD
    Cooke, LW
    Meltzer, LT
    Whetzel, SZ
    Shih, YH
    Wustrow, DJ
    Wise, LD
    MacKenzie, RG
    Georgic, LM
    Heffner, TG
    Pugsley, TA
    NEUROPHARMACOLOGY, 2000, 39 (07) : 1197 - 1210
  • [6] PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT1A agonist actions.: II.: Preclinical behavioral effects
    Corbin, AE
    Meltzer, LT
    Ninteman, FW
    Wiley, JN
    Cristoffersen, CL
    Wustrow, DJ
    Wise, LD
    Pugsley, TA
    Heffner, TG
    NEUROPHARMACOLOGY, 2000, 39 (07) : 1211 - 1221
  • [7] The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D1 agonist and D2 antagonist
    Sridhar Natesan
    Greg E. Reckless
    Karen B. L. Barlow
    John Odontiadis
    José N. Nobrega
    Glen B. Baker
    Susan R. George
    David Mamo
    Shitij Kapur
    Psychopharmacology, 2008, 199 : 275 - 289
  • [8] The antipsychotic potential of l-stepholidine -: a naturally occurring dopamine receptor D1 agonist and D2 antagonist
    Natesan, Sridhar
    Reckless, Greg E.
    Barlow, Karen B. L.
    Odontiadis, John
    Nobrega, Jose N.
    Baker, Glen B.
    George, Susan R.
    Mamo, David
    Kapur, Shitij
    PSYCHOPHARMACOLOGY, 2008, 199 (02) : 275 - 289
  • [9] The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors
    Zhang, W
    Bymaster, FP
    PSYCHOPHARMACOLOGY, 1999, 141 (03) : 267 - 278
  • [10] Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats
    Roman, V.
    Gyertyan, I.
    Saghy, K.
    Kiss, B.
    Szombathelyi, Zs.
    PSYCHOPHARMACOLOGY, 2013, 226 (02) : 285 - 293